Prexasertib is a novel inhibitor of checkpoint kinase 1. The primary objective of this study was to evaluate prexasertib tolerability in Japanese patients with advanced There were no discontinuations due to adverse events or deaths. The prexasertib pharmacokinetics displayed dose-independent and time-independent behavior across both dose levels, similar to the profile observed in the US-based phase 1 study.
to DNA damage. 1, 2 The proteins ataxia telangiectasia mutated and RAD3-related (ATR) and/or ataxia telangiectasia mutated (ATM) are activated in response to DNA damage, which in turn phosphorylate CHK1 and checkpoint kinase 2 (CHK2), respectively. 3 p53 is another critical mediator of the response to DNA damage. It is activated through phosphorylation by CHK2 and ATM, and participates in a parallel pathway to ATR and CHK1. 3 CHK1 can also regulate DNA replication checkpoints by maintaining or enhancing the inhibitory phosphorylation of cyclin-dependent kinases, which are key drivers of cell cycle progression. 2 In addition, CHK1 can stabilize replication forks and promote DNA repair, control initiation of DNA replication, and coordinate mitosis. 2 Inhibitors of CHK1 have been developed as combination therapy to augment the efficacy of DNA-damaging chemotherapeutics. [4] [5] [6] [7] Given the central role that CHK1 has in DNA replication and regulation of the cell cycle, inhibitors of CHK1 are also being developed as single-agent therapies. 3, 8 Prexasertib (LY2606368) is an inhibitor of CHK1 and, to a lesser extent, CHK2 that can disrupt DNA replication, induce DNA damage, and prevent DNA repair, eventually leading to cell death via interruption of DNA replication. 1 Preclinical studies in solid tumor models have shown that prexasertib as a single agent, or in combination with other agents, has both in vitro and in vivo antitumor activity. 1, 9, 10 Prexasertib, in combination with cetuximab and irradiation, has also been shown to have antitumor effects in head and neck squamous cell carcinoma (SCC) in vitro and in vivo. tion. 8 The most common drug-related grade 3 or 4 treatment-emergent adverse events (TEAE) in the dose-escalation portion of this phase 1 study were reversible neutropenia, leukopenia, anemia, thrombocytopenia and fatigue. 8 Two patients (4%) had a partial response, 1 with SCC of the anus and 1 with SCC of the head and neck, and 15 patients (33%) with various cancer types had a best overall response (BOR) of stable disease. 8 In a phase 2 single-center study of prexasertib in 28 women with BRCA wild-type recurrent high-grade serous ovarian cancer, partial responses were reported for 8 patients (29%) in the intention-to-treat population, with the most common grade 3 or 4 TEAE being neutropenia, leukopenia, thrombocytopenia and anemia. 12 This phase 1 study was conducted to investigate the safety, tolerability, pharmacokinetics (PK) and antitumor activity of prexasertib in Japanese patients with advanced solid tumors. This study is registered with ClinicalTrials.gov, identifier NCT02514603. 
| PATIENTS AND METHODS

| Eligibility
| Safety evaluations
A DLT was defined as an adverse event (AE) during cycle 1 (the first 14 days of treatment) that was possibly related to prexasertib and fulfilled any of the following criteria using the National Cancer Insti- 
| Efficacy evaluations
Patients were assessed for tumor measurement by computed tomography scan or mRI using RECIST version 1.1. The BOR was defined as the best response recorded from the start of the treatment until disease progression. The best response of stable disease was defined as disease that did not meet the criteria for complete response, partial response or progressive disease and had been evaluated approximately 4 weeks (defined as ≥28 days) after the date of the first dose.
| RESULTS
| Patients
Between 16 October 2015 and 25 January 2017, 12 eligible patients were enrolled and treated, 6 with prexasertib 80 mg/m 2 and 6 with prexasertib 105 mg/m 2 . Two-thirds of patients (66.7%) were male, the median age was 62 years, and most patients (58.3%) had an ECOG performance status of 1 ( Table 1 ). All except 1 patient had received at least 1 (median, 4; range, 0-10) prior systemic treatment (91.7%), two-thirds had received prior surgery (66.7%), and half had received prior radiotherapy (50.0%). Twenty-five percent of patients had esophageal SCC. The cancer types of malignant neoplasm of thymus, rhabdomyosarcoma, small intestine carcinoma and transitional cell carcinoma had not been studied in the previous phase 1 study of prexasertib treatment in the US. 
| Pharmacokinetics
The PK profile of prexasertib displayed a multiexponential decline in plasma concentrations with dose-dependent increases in systemic exposure and consistent PK profiles after single-dose and multipledose administration across the dose range investigated. Figure 1 shows the arithmetic mean plasma concentration vs time profiles of prexasertib after a single dose in cycle 1 ( Figure 1A) and multiple doses in cycle 2 ( Figure 1B ). There was no intercycle accumulation of prexasertib between cycle 1 and cycle 2 in both treatment groups (Table 3) . Mean t 1/2 values were consistent across different dose levels (Table 3) . A small-to-moderate degree of interpatient variability (mean percent coefficient of variation range: 7%-25%) in prexasertib CL was observed in both treatment groups. The CL and V ss were consistent after repeat administration at both dose levels (Table 3) , indicating dose-independent and time-independent PK behavior. | 3221
| DISCUSSION
The results of this study confirm the tolerability of prexasertib administered at 80 and 105 mg/m 2 in Japanese patients with advanced solid tumors. The observed safety and tolerability profile, including DLT, in Japanese patients was consistent with the known safety profile for prexasertib in the US phase 1 study. 8 Prexasertib PK displayed dose-independent and time-independent behavior across both dose levels investigated, and was consistent with the PK in non-Japanese patients. 8 Of 11 patients, 8 had a BOR of stable disease and no responders were reported. The limitations of this study include the relatively small patient cohorts and the heterogeneity of the tumor types investigated.
The most common toxicities associated with prexasertib were hematologic, with a similar incidence and severity to that observed in non-Japanese patients. 8 Although there were 2 patients with DLT of febrile neutropenia, both recovered and continued the study treatment at a reduced dose. Six patients reported grade 4 neutropenia related to the study drug. Neutrophil counts in these patients reached a nadir with almost the exact same timing, indicating that the onset of neutropenia was predictable. A similar incidence of neutropenia with prexasertib was reported in the previous phase 1 trial conducted in non-Japanese patients. 8 The incidence of neutropenia observed with prexasertib is higher than that reported for AZD7762 (CHK1/CHK2 inhibitor) and MK-8776 (CHK1 inhibitor). 4, 5, 13 However, non-hematologic TEAE occurred at lower rates and at a lower severity with prexasertib compared to other CHK1 inhibitors. In addition, consistent with the previous phase 1 trial conducted in non-Japanese patients, 8 there were no clinically significant cardiac toxicities or AE related to QT prolongation with prexasertib, whereas other CHK1 inhibitors have been associated with cardiotoxicity, including myocardial infarction and significant QTc changes. 4, 13 Regardless, direct comparisons are difficult because the majority of experience with other CHK1 inhibitors is in combination with cytotoxic agents and not as single-agent treatments.
In contrast to the phase 1 trial conducted in non-Japanese with maximum tumor shrinkage from baseline of 20% and 13%.
The phase 1 trial conducted in non-Japanese patients observed tumor shrinkage in 10 of 34 patients, with many of these cases occurring in SCC. 8 Squamous cell carcinoma may harbor increased levels of replication stress and/or DNA damage response, which may contribute to an increased response to CHK1/2 inhibitors. 3 On the basis of these findings, cohorts in SCC are being evaluated in the dose-expansion phase of the phase 1 study in non-Japanese patients. 8 Prexasertib PK in Japanese patients displayed dose-independent and time-independent PK behavior at both dose levels investigated.
After administration of prexasertib 105 mg/m 2 , the geometric mean AUC (0-72) achieved the median AUC (0-72) of 1896 ng h/mL predicted from the nonclinical Calu-6 xenograft PK/pharmacodynamic model to achieve the maximal tumor response following prexasertib monotherapy. 8 In addition, after administration of prexasertib105 mg/m 2 in cycle 1 and cycle 2, 8 of 9 (89%) of the noncompartmental AUC (0-72) values were greater than the median AUC predicted to correlate with the maximum tumor response after prexasertib monotherapy. 8 The mean average prexasertib plasma concentrations over the first 72 hours (C av,72 ) after administration of 105 mg/m 2 in cycle 1 and cycle 2 were also greater than the IC 50 (14.1 ng/mL) derived from the single-agent Calu-6 xenograft model. 8 Prexasertib PK are, therefore, suitable for achieving the median human exposure predicted from the nonclinical Calu-6 xenograft PK/ pharmacodynamic model. 8 Prexasertib PK for Japanese patients are also consistent with the PK reported in the US-based phase 1 study in non-Japanese patients. 8 Taken together, these data indicate that prexasertib PK in Japanese patients are suitable for minimizing intercycle accumulation and for achieving the median predicted maximum efficacious systemic exposure following intravenous administration of 105 mg/m 2 once every 14 days.
In conclusion, the overall safety findings in this study were consistent with the known safety profile for prexasertib, and tolerability at the recommended dose of 105 mg/m 2 was confirmed in Japanese patients with advanced solid tumors, including those with cancer types not previously investigated with prexasertib treatment.
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